Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer-Reference-Cited by-同舟云学术

Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer

Published:2009-01 Issue: Volume:31 Page:2332-2348
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Tevaarwerk Amye J.,Kolesar Jill M.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference74 articles.

1. The deaf and the dumb: The biology of ErbB-2 and ErbB-3;Citri;Exp Cell Res.,2003

2. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling;Graus-Porta;EMBO J.,1997

3. The ErbB signaling network: Receptor heterodimerization in development and cancer;Olayioye;EMBO J.,2000

4. Untangling the ErbB signalling network;Yarden;Nat Rev Mol Cell Biol.,2001

5. Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells;Huang;Br J Cancer,2002

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Review of HER2 in Cancer Biology and Therapeutics;Genes;2024-07-11

2. A Lipophilic Salt Form to Enhance the Lipid Solubility and Certain Biopharmaceutical Properties of Lapatinib;Molecular Pharmaceutics;2024-06-27

3. Inhibition of EGFR/ErbB does not protect againstC. difficiletoxin B;2024-05-14

4. In silico analysis and characterization of potential inhibitors of MmaA3, a methoxy mycolic acid synthase from Mycobacterium tuberculosis;Journal of Biomolecular Structure and Dynamics;2024-05-10

5. Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance;Biomedicines;2024-04-25